Aytu BioPharma Subleases A Portion Of Its Manufacturing Facility

Aytu BioPharma, Inc. a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, entered into an agreement with AMT Manufacturing Solutions, LLC ("AMTMS"), a newly established, full service Contract Manufacturing Organization ("CMO"), to sublease 22,909 square feet of Aytu's Grand Prairie, TX manufacturing facility. This sublease represents over 30% of the Company's FDA and DEA-approved pharmaceutical manufacturing facility. In addition, commencing as early as April 1, 2024, but no later than December 31, 2024, the sublease will be expanded to include the rest of the manufacturing facility, a total of 77,112 square feet.

"This is a significant step forward in our goal to improve the margins of our ADHD products in both the short-term through overhead expense reduction and the longer-term as we transfer the manufacturing of our ADHD brands to a contract manufacturer," commented Josh Disbrow, Aytu's Chief Executive Officer. "We are pleased to be working with AMTMS to allow us to reduce our monthly operating expenses and to materially reduce the costs associated with our Grand Prairie facility."

"We look forward to launching our AMTMS CMO operations from within this world-class pharmaceutical manufacturing plant," said Timothy Rogers, Chief Executive of Adaptive Medical Technologies, AMTMS' parent company.

Gerry Chastelet, Chief Executive Officer of AMTMS, added, "This immediate move into part of Aytu's existing facility greatly improves our time to market in launching the AMTMS manufacturing business, while our eventual utilization of the entire FDA/DEA pharmaceutical manufacturing facility addresses our longer-term strategy for providing a wide range of CMO services for both nutraceutical and pharmaceutical opportunities."